This phase 3 RCT compared robot-assisted minimally invasive esophagectomy (RAMIE) vs conventional minimally invasive esophagectomy (MIE) in 202 patients with resectable esophageal or esophagogastric junction adenocarcinoma (cT1-4a, cN0-3, cM0) across 4 high-volume centers in Europe (2021–2025), with follow-up up to 5 years.
RAMIE yielded a significantly higher median lymph node count than MIE (36 vs 32; P = .005), with comparable R0 resection rates (99.0% vs 97.0%), similar postoperative complication rates, low 90-day mortality (1.0% vs 3.0%; P = .62), and no difference in 1-year survival.
The trial was conducted at 4 high-volume tertiary referral centers, which may limit generalizability to lower-volume settings; follow-up survival data beyond 1 year are not yet mature; and the clinical significance of the 4-node difference in lymph node yield on long-term oncological outcomes remains to be established.
RAMIE achieves a more extensive lymphadenectomy than conventional MIE without added surgical risk, supporting its use as a standard approach for esophageal and esophagogastric junction adenocarcinoma in centers with robotic expertise.
Explore related topics